Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.80 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.80 |
| ▸ | APP | P05067 | 2/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raloxifene Core SCHEMBL2567321 | 0.89 | ESR1 (1.00) | ESR1ESR2APPHSD17B1HSD17B2 | |
| Raloxifene Core SCHEMBL29941293 | 0.89 | ESR1 (1.00) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL3139631 | 0.83 | ESR1 (1.00) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL19171602 | 0.83 | ESR1 (0.80) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL13071222 | 0.83 | ESR1 (0.80) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL7643423 | 0.82 | ESR1 (1.00) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL27364075 | 0.80 | ESR1 (0.76) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL9977515 | 0.79 | ESR1 (0.61) | ESR1ESR2APPHDAC3HDAC1 | |
| SCHEMBL498648 | 0.79 | ESR2 (0.73) | ESR1ESR2APPHDAC6ALOX15 | |
| SCHEMBL3148543 | 0.79 | ESR1 (0.73) | ESR1ESR2APPHSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753387-B2 | Compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753387-B2 | Compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-3889135-B1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-08-02 | — | — | EP | disclosed |
| EP-3889135-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3583092-B1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2021-05-26 | — | — | EP | disclosed |
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3233828-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| EP-2430014-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ESR1 4094/4885ESR2 4021/4885APP 3888/4885 |
| US-11753387-B2 | Compounds for optically active devices | PDE6C, PDE6A, PDE6D | ESR1 1260/4885ESR2 3107/4885APP 899/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ESR1 4094/4885ESR2 4021/4885APP 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.